Pityriasis versicolor: the AU general practice guide to diagnosis and treatment

Pityriasis versicolor is one of the most common skin conditions in Australia, particularly in tropical and subtropical regions where humidity and heat create ideal conditions for Malassezia yeast overgrowth. Up to 50% prevalence has been recorded in Far North Queensland and the Top End during the warmer months. Despite its frequency, it is regularly misidentified — either as vitiligo when the patches are hypopigmented, or as an allergy or “tan problem” when first noticed after summer.

The condition is not contagious and carries no systemic risk in otherwise healthy people. Its main impact is cosmetic, and that cosmetic impact can be significant — particularly for young adults, dark-skinned individuals where the contrast is more striking, and anyone whose work or recreation exposes their torso.

Understanding two things resolves the majority of patient distress: the yeast is a permanent resident on everyone’s skin and disease simply reflects a temporary imbalance, and pigment recovery after treatment is slow by biology — not a sign of treatment failure.

A. Core clinical — the AU general-practice framework

What causes it

The Australasian College of Dermatologists describes pityriasis versicolor as a superficial fungal infection of the outer skin layer (stratum corneum) caused by overgrowth of lipophilic Malassezia yeast — predominantly M. globosa and M. furfur in Australian populations. Malassezia is a normal commensal that colonises everyone’s skin from puberty, when sebum production rises.

Disease reflects a shift from the harmless yeast form to a hyphal (mycelial) form that is pathogenic. Predisposing factors are heat, humidity, hyperhidrosis, oily skin, occlusive clothing, immunosuppression, oral corticosteroids, oral contraceptive pill, pregnancy, and malnutrition. Topical oils and oil-based sunscreens provide an additional lipid substrate that supports the organism.

The characteristic pallor arises because Malassezia produces azelaic acid — a compound that competitively inhibits tyrosinase in melanocytes, reducing melanin synthesis. This is temporary: once the yeast is eliminated, tyrosinase activity recovers, but the process takes weeks to months.

How it presents

The classic presentation is multiple oval or round patches, 5 mm to 2 cm, on the chest, back, neck, and upper arms — areas where sebum density is highest. The patches have a fine, powdery scale that is often invisible until the skin is gently stretched or scratched — this is Besnier’s sign, and it is the bedside diagnostic clue that distinguishes pityriasis versicolor from vitiligo (no scale) and pityriasis alba (less distinct scale in children).

Colour is variable — hence “versicolor.” On tanned or darker skin, patches appear paler than surrounding skin, often most obvious in summer when surrounding skin tans and the affected areas don’t. On untanned or fairer skin, patches often appear as faintly pink or light brown. Both presentations reflect the same underlying process.

Pruritus is present in about 20% of cases; most people are asymptomatic until the cosmetic change is noticed.

Confirming the diagnosis

Diagnosis is clinical in typical presentations. Therapeutic Guidelines (eTG) support confirming with KOH microscopy of a skin scraping when there is any diagnostic uncertainty — the pathognomonic “spaghetti and meatballs” pattern of short curved hyphae and clusters of spores is unmistakeable. This is a rebatable MBS item (69333). Wood’s lamp examination provides yellow-green fluorescence in approximately 30% of cases, useful for mapping distribution before treatment.

Fungal culture is rarely necessary and requires lipid-supplemented Sabouraud agar — clinically it adds little beyond confirming the genus.

Treatment pathway

Per eTG Dermatology and the Australasian College of Dermatologists, treatment follows a stepwise approach:

Topical antifungals — first-line for limited or first episodes:

Ketoconazole 2% shampoo (Nizoral) is the preferred topical agent. The patient applies it to affected skin when dry, allows it to lather, leaves it on for 5–10 minutes, then rinses — daily for 7–14 days. The key instruction is that it is applied to dry skin and left to act; it should not be washed off immediately as a standard shampoo. Selenium sulfide 2.5% shampoo (Selsun) is a cheaper alternative using the same method; it has a mild sulphurous odour and can stain lighter fabrics. For limited patches, clotrimazole or miconazole cream applied twice daily for 2–4 weeks is practical.

Oral antifungals — for extensive, refractory, or cosmetically distressing disease:

The Australian Medicines Handbook (AMH) lists itraconazole 200 mg daily for 7 days as the first-line oral regimen; a single 400 mg dose is used for milder recurrent disease. Itraconazole must be taken with food and an acidic drink (such as cola) for adequate absorption, and its CYP3A4 inhibition requires a drug interaction check — statins (particularly simvastatin and lovastatin), warfarin, and calcium channel blockers are important interactions. Fluconazole 400 mg as a single dose or 150 mg weekly for 2–4 weeks is an acceptable alternative with fewer drug interactions, useful in patients with complex medication lists.

Oral ketoconazole must not be used. The TGA withdrew oral ketoconazole for superficial fungal infections in 2013 due to clinically significant hepatotoxicity risk. It is medico-legally indefensible and pharmacologically unnecessary given the alternatives.

Maintenance to prevent recurrence:

Without maintenance, approximately 80% of patients have a recurrence within 2 years. Monthly ketoconazole 2% shampoo applied once to the prone areas (chest, back, shoulders) for one day each month substantially reduces this risk, per eTG. For patients with particularly frequent recurrences, monthly itraconazole 200 mg twice daily for one day is an alternative pulse strategy.

B. Pigment recovery — the most important counselling point

Clearing the infection and clearing the skin discolouration are two separate biological processes. This is the single most important piece of information to give patients, and failure to communicate it generates unnecessary repeat consultations and repeat prescriptions.

After the yeast is eliminated, the inhibitory azelaic acid effect on melanocytes resolves — but melanocyte function recovers slowly. Repigmentation of previously hypopigmented macules takes weeks to months. The proof of cure is not even skin tone — it is absence of scale on the lesions (negative Besnier’s sign on examination, or no scale on stretching at home). If the skin is smooth and scale-free, the infection has cleared even when the colour difference persists.

Gentle sun exposure — with broad-spectrum sunscreen applied beforehand — accelerates blending of the pigmentation over time as surrounding tanned skin and recovering macules converge. It does not speed the underlying melanocyte recovery, but it helps cosmetically.

Patients who are told this in advance are far less likely to present believing treatment has failed and requesting further antifungal courses for what is a normal healing trajectory.

C. Distinguishing pityriasis versicolor from other hypopigmented conditions

The clinical differential in general practice includes several important possibilities:

Vitiligo is the most critical distinction. Vitiligo involves complete destruction of melanocytes — the patches are chalk-white with no residual pigment, no scale, and bright white under Wood’s lamp (compared to yellow-green for versicolor). Distribution also differs: vitiligo commonly affects the face, hands, knuckles, elbows, and perioral area, not predominantly the trunk. Any patient with truly depigmented (chalk-white) patches should be referred for dermatological assessment rather than presumed to have versicolor.

Pityriasis alba produces hypopigmented patches in children and adolescents, predominantly on the face, and is part of the atopic/eczema spectrum. There is often background dryness and no association with sweating.

Malassezia (Pityrosporum) folliculitis is caused by the same organism — overgrowth of Malassezia in hair follicles — but presents as monomorphic itchy acne-like pustules on the chest, back, and shoulders. It is frequently misdiagnosed as acne and worsened by antibiotics. Treatment is identical to pityriasis versicolor: topical or oral azoles, not antibiotics.

Hypopigmented mycosis fungoides is a rare but must-not-miss variant of cutaneous T-cell lymphoma. Atypical persistent hypopigmented patches that fail to scale and do not respond to antifungal treatment warrant skin biopsy.

D. Australian operations

Pathology and imaging items (MBS): Standard GP consultations are billed under items 23, 36, or 44 depending on time and complexity. Skin scraping KOH microscopy is item 69333 (rebatable by any GP). Baseline LFTs (item 66512) are indicated before commencing oral azoles, particularly itraconazole or extended fluconazole. ECG (item 11707) is reasonable before itraconazole in elderly patients or those with cardiac history due to QT considerations.

PBS prescribing: Ketoconazole 2% shampoo (Nizoral) and selenium sulfide 2.5% shampoo (Selsun) are over-the-counter. Topical clotrimazole and miconazole creams are OTC or general schedule. Itraconazole capsules are available on PBS general schedule (Restricted Benefit) for confirmed superficial fungal infections. Fluconazole 150 mg is on PBS for vulvovaginal candidiasis; for pityriasis versicolor a private prescription may be required depending on the prescribing context.

ATSI considerations: The prevalence of pityriasis versicolor is high in Aboriginal and Torres Strait Islander communities in tropical and remote areas. The ATSI Health Assessment (item 715) provides an opportunistic entry point for skin examination and education in these communities.

E. Special populations

Pregnancy: Topical ketoconazole shampoo and selenium sulfide are considered acceptable in pregnancy — systemic absorption from topical application is minimal. Oral azoles (itraconazole Category B3; fluconazole Category D) should be deferred until after delivery and breastfeeding is complete when possible. Pityriasis versicolor commonly flares during pregnancy due to hormonal shifts in sebum production; reassurance and topical-only management is appropriate in most cases.

Immunocompromised patients (HIV, transplant, long-term corticosteroids, Cushing syndrome): Extensive, atypical, or unusually refractory pityriasis versicolor should prompt investigation for underlying immune compromise. These patients have a lower threshold for oral therapy and may require longer maintenance schedules.

Children: Disease is rare before puberty when sebum production is low. In the minority of cases that occur in children, topical therapy is preferred; oral azoles are generally avoided. Cradle-cap and facial seborrhoeic dermatitis in young children may have a Malassezia component and overlap with pityriasis versicolor in differential.

Athletes and outdoor workers: High-sweat occupations and sports — military, agriculture, mining in tropical regions — carry elevated risk. Monthly maintenance shampoo during the hotter months is a practical preventive strategy.

When to escalate

Refer to dermatology when:

• Treatment has failed after two appropriate courses (one topical, one oral azole)
• Patches are atypical — no scale, not responding to antifungal, unusual distribution — where hypopigmented mycosis fungoides needs exclusion
• Severe immunocompromise (HIV, transplant) with extensive or progressive disease
• Cosmetic distress causing significant psychological impact warranting specialised dermatology review

Urgent same-week dermatology referral for suspected hypopigmented mycosis fungoides.

What this article is and is not

This article draws on current Australian general practice evidence — Therapeutic Guidelines (eTG), the Australasian College of Dermatologists, and the Australian Medicines Handbook — alongside the TGA’s oral ketoconazole withdrawal guidance and BMJ Best Practice. It is general health information for educational purposes and does not constitute personal medical advice or create a doctor–patient relationship.

For Australian consumer-friendly information: HealthDirect, Better Health Channel, and the Australasian College of Dermatologists patient information.

---

Sources cited

1. Therapeutic Guidelines (eTG) — Dermatology: Pityriasis versicolor
2. Australasian College of Dermatologists — Pityriasis versicolor A–Z
3. Australian Medicines Handbook
4. TGA — Oral ketoconazole hepatotoxicity warning 2013
5. HealthDirect — Tinea versicolor / Pityriasis versicolor
6. Better Health Channel — Skin fungal infections
7. BMJ Best Practice — Pityriasis versicolor